Bora Group to Acquire MacroGenics’ GMP Manufacturing Operations
Bora Group has announced a definitive agreement to acquire the GMP manufacturing operations of MacroGenics, Inc. for $122.5 million, including a biologics drug substance facility in Rockville, Maryland.
This strategic acquisition significantly expands Bora Biologics’ U.S. drug substance capacity and strengthens our integrated end‑to‑end biologics platform. The Rockville site adds five 2,000‑liter and two 500‑liter single‑use bioreactors, fully integrated QC and analytical laboratories, and an established commercial and clinical manufacturing backlog. Upon closing, Bora Biologics’ total drug substance capacity will reach 20,000 liters (SUB), further enhancing our ability to support programs from development through commercial supply.
The transaction also includes a long‑term CDMO service agreement and existing commercial-stage monoclonal antibody programs, reinforcing Bora’s position as a trusted U.S.-based biologics manufacturing partner.
